# Phase 2/3 lymphoma trials recruiting: 25 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 25 trials in phase 2/3 for lymphoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2/3 lymphoma trials: 25 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2-3/lymphoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 25
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 5, 2026 | NCT07917754 | A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010) | Merck Sharp & Dohme LLC | Phase 2/3 | Not yet recruiting | Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma | 470 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917754) |
| September 30, 2026 | NCT07848672 | Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization | The Affiliated People's Hospital of Ningbo University | Phase 2/3 | Not yet recruiting | Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Hematopoietic Stem Cell Mobilization... | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07848672) |
| July 24, 2026 | NCT07724457 | Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma | National Cancer Institute (NCI) | Phase 2/3 | Recruiting | Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory Burkitt... | 271 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07724457) |
| July 17, 2026 | NCT07712588 | Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) | Dizal Pharmaceuticals | Phase 2/3 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 880 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07712588) |
| June 8, 2026 | NCT07634471 | A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) | Merck Sharp & Dohme LLC | Phase 2/3 | Recruiting | Follicular Lymphoma | 960 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07634471) |
| May 6, 2026 | NCT07570173 | A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) | Merck Sharp & Dohme LLC | Phase 2/3 | Recruiting | B-cell Acute Lymphoblastic Leukemia | 340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07570173) |
| March 30, 2026 | NCT07502118 | NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) | Health Institutes of Turkey | Phase 2/3 | Recruiting | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma, Diffuse... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07502118) |
| February 5, 2026 | NCT07389616 | A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 2/3 | Recruiting | Peripheral T Cell Lymphoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07389616) |
| October 1, 2025 | NCT07202091 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) | Monash University | Phase 2/3 | Recruiting | Myeloma, Leukemia, Non Hodgkin&#39;s Lymphoma | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07202091) |
| October 1, 2025 | NCT07202078 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) | Monash University | Phase 2/3 | Recruiting | Myeloma, Non Hodgkin&#39;s Lymphoma, Leukemia | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07202078) |
| October 1, 2025 | NCT07202065 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) | Monash University | Phase 2/3 | Recruiting | Myeloma, Non Hodgkin&#39;s Lymphoma, Leukemia | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07202065) |
| October 1, 2025 | NCT07202052 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) | Monash University | Phase 2/3 | Recruiting | Myeloma, Non-Hodgkin's Lymphoma, Leukemia | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07202052) |
| July 24, 2025 | NCT07084662 | Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B Lymphoma | Sun Yat-sen University | Phase 2/3 | Recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07084662) |
| July 18, 2025 | NCT07072585 | Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and... | Children's Oncology Group | Phase 2/3 | Not yet recruiting | Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic... | 1,708 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07072585) |
| March 26, 2025 | NCT06895538 | Comparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy | Peking University First Hospital | Phase 2/3 | Recruiting | Leukemia, MDS, Lymphoma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06895538) |
| March 18, 2025 | NCT06882057 | Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol | Institute of Hematology & Blood Diseases Hospital, China | Phase 2/3 | Recruiting | Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL) | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06882057) |
| January 8, 2025 | NCT06764238 | Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol | Institute of Hematology & Blood Diseases Hospital, China | Phase 2/3 | Recruiting | Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL) | 1,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06764238) |
| January 1, 2025 | NCT06756152 | Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with... | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 2/3 | Recruiting | Biphenotypic Acute Leukemia, Acute Lymphoblastic Leukemia, Myeloblastic Leukemia, Bilinear Leukemia, Malignant... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06756152) |
| September 23, 2024 | NCT06607419 | Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia | Shanghai Jiao Tong University School of Medicine | Phase 2/3 | Recruiting | B-Cell Lymphoblastic Leukemia | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06607419) |
| August 12, 2024 | NCT06548347 | A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma | Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 2/3 | Not yet recruiting | Peripheral T Cell Lymphoma | 606 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06548347) |
| April 9, 2024 | NCT06355401 | Maintenance Hormonal Therapy and DLBCL | Sohag University | Phase 2/3 | Not yet recruiting | Diffuse Large B Cell Lymphoma | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06355401) |
| August 14, 2023 | NCT05991388 | A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | University of Birmingham | Phase 2/3 | Recruiting | B-cell Non Hodgkin Lymphoma | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05991388) |
| March 15, 2023 | NCT05770037 | DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers | Cancer Research UK | Phase 2/3 | Recruiting | Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05770037) |
| January 10, 2023 | NCT05678621 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension | Monash University | Phase 2/3 | Recruiting | Haematological Malignancy, Hypogammaglobulinemia | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05678621) |
| December 1, 2021 | NCT05139017 | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large... | Merck Sharp & Dohme LLC | Phase 2/3 | Recruiting | DLBCL, Diffuse Large B-Cell Lymphoma | 290 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05139017) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Monash University | 5 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 4 |
| Institute of Hematology & Blood Diseases Hospital, China | 2 |
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 1 |
| Cancer Research UK | 1 |
| Sun Yat-sen University | 1 |
| [Shanghai YingLi Pharmaceutical Co. Ltd.](https://specstream.ai/data/clinical-trials/company/shanghai-yingli-pharmaceutical-co-ltd) | 1 |
| National Cancer Institute (NCI) | 1 |
| Sohag University | 1 |
| University of Birmingham | 1 |
| Peking University First Hospital | 1 |
| [Dizal Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/dizal-pharmaceuticals) | 1 |
| Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 1 |
| Shanghai Jiao Tong University School of Medicine | 1 |
| Children's Oncology Group | 1 |
| Health Institutes of Turkey | 1 |
| The Affiliated People's Hospital of Ningbo University | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 9 |
| Australia | 8 |
| United Kingdom | 3 |
| United States | 3 |
| France | 3 |
| Greece | 3 |
| Israel | 3 |
| Italy | 3 |
| Turkey (Türkiye) | 3 |
| Hong Kong | 3 |
| Netherlands | 2 |
| New Zealand | 2 |
| Sweden | 2 |
| Argentina | 2 |
| Chile | 2 |
| Poland | 2 |
| South Korea | 2 |
| Spain | 2 |
| Canada | 2 |
| Denmark | 2 |
| Japan | 2 |
| Austria | 1 |
| Belgium | 1 |
| Taiwan | 1 |
| Russia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Waterproofing contractors in the United States](https://specstream.ai/data/businesses/waterproofing-contractors/united-states)
- [Sawmills in the United States](https://specstream.ai/data/businesses/sawmills/united-states)
- [Occupational safety services in the United States](https://specstream.ai/data/businesses/occupational-safety-services/united-states)
- [Hydro jetting companies in the United States](https://specstream.ai/data/businesses/hydro-jetting-companies/united-states)
- [Elevator companies in the United States](https://specstream.ai/data/businesses/elevator-companies/united-states)
- [Business brokers in the United States](https://specstream.ai/data/businesses/business-brokers/united-states)
